viru
infect
respiratori
tract
affect
peopl
place
time
throughout
life
virus
involv
averag
child
age
five
year
adult
develop
countri
experi
four
five
two
four
infect
year
respect
although
mani
infect
rel
mild
lifethreaten
dougla
edelstein
said
three
hundr
million
case
acut
respiratori
diseas
occur
unit
state
year
account
one
hundr
fifti
million
visit
physician
cost
ill
exce
one
billion
dollar
exclus
time
lost
work
statist
adjust
popul
direct
countri
size
problem
demand
much
gener
physician
time
import
focus
attent
epidemiologist
microbiologist
pharmaceut
compani
mani
other
virus
caus
respiratori
tract
infect
man
includ
rna
dna
virus
six
famili
includ
mani
virus
caus
respiratori
symptom
princip
tissu
organ
infect
respiratori
tract
famili
list
tabl
togeth
data
finer
classif
subfamili
genera
subgenera
number
distinct
type
viru
group
number
caus
human
respiratori
infect
thu
six
famili
encapsul
subdivis
virus
caus
respiratori
tract
infect
man
remaind
caus
type
infect
infect
speci
exact
number
complic
rhinovirus
serotyp
known
mani
probabl
exist
influenza
b
viru
exhibit
continu
genet
chang
produc
new
antigen
variant
year
respiratori
tract
consid
stratifi
horizont
level
begin
nasal
passag
descend
sequenti
throat
trachea
bronchi
bronchiol
alveoli
conveni
divid
respiratori
tract
manner
sinc
mani
virus
predilect
infect
particular
level
associ
shown
tabl
thu
common
cold
limit
nasal
passag
caus
commonli
rhinovirus
virolog
rhinovirus
belong
famili
picornavirida
distinguish
member
famili
higher
particl
densiti
acid
labil
limit
intestin
infect
rel
heat
stabil
resist
varieti
deterg
surviv
sever
hour
even
day
outsid
bodi
viru
particl
contain
intern
rna
singlestrand
posit
polar
surround
capsid
capsomer
arrang
icosahedr
symmetri
particl
approxim
nm
diamet
rhinovirus
replic
human
cell
less
well
cell
primat
condit
growth
rel
low
ph
low
temperatur
aerat
cell
cultur
condit
cytopath
effect
observ
growth
cycl
take
hour
infect
cell
yield
viru
particl
crossneutr
test
indic
distinct
serolog
type
share
epitop
exist
hamparian
et
al
epidemiolog
frequenc
respiratori
infect
year
adult
higher
incid
children
conmion
cold
due
rhinovirus
number
serotyp
circul
concurr
evid
crossimmun
infect
tend
common
spring
autumn
spread
larg
small
droplet
nasal
secret
infect
person
direct
spread
nasal
secret
via
hand
hand
contact
autoinocul
nasal
conjunctiv
mucosa
via
inanim
object
infect
initi
littl
viru
virus
surviv
long
period
outsid
bodi
peak
titer
appear
nasal
secret
day
onset
symptom
viru
persist
day
howev
viru
secret
continu
week
serum
antibodi
respons
seen
affect
patient
local
iga
respons
immun
last
year
multipl
circul
serotyp
give
litd
protect
clinic
diseas
gwaltney
pathogenesi
pathogenesi
rhinoviru
infect
understood
virus
grow
high
titer
nasal
epithelium
biopsi
antigenposit
nasal
mucosa
cell
show
litd
patholog
chang
infect
caus
progress
loss
ciliat
epitheli
cell
inflammatori
cell
infiltr
edema
hyperemia
seromucin
exud
hendley
viru
replic
predominantli
nasal
mucosa
cell
type
nare
throat
rel
resist
clinic
featur
incub
period
day
viru
titer
increas
symptom
nasal
obstruct
discharg
sneez
cough
occur
sore
throat
erythema
headach
may
experienc
fever
system
symptom
usual
absent
symptom
usual
improv
day
symptom
may
last
day
case
day
complic
includ
sinus
otiti
media
rhinovirus
isol
middl
ear
often
bacterium
found
conjunct
viru
small
particl
infect
caus
tracheobronch
bronchiol
exacerb
asthma
chronic
bronchiti
commonli
precipit
rhinoviru
infect
diagnosi
rhinovirus
recov
infect
person
inocul
nasal
secret
onto
monkey
human
cell
incub
roller
drum
maxim
cytopath
effect
appear
day
infect
alnakib
tyrrel
isol
serotyp
use
batteri
neutral
antisera
variou
combin
seldom
carri
except
research
purpos
lack
specif
treatment
mean
laboratori
diagnosi
seldom
attempt
treatment
specif
treatment
rhinoviru
infect
treatment
recommend
reliev
symptom
nasal
decongest
use
reliev
obstruct
gargl
reliev
sore
throat
analges
use
necessari
cough
sever
suppress
codein
dextromethorphan
given
multipl
antigen
type
make
vaccin
develop
impract
volunt
studi
shown
inactiv
vaccin
litd
protect
effect
local
appli
interferon
suppress
viru
replic
longterm
use
cytotox
caus
irrit
bleed
ulcer
patient
virolog
coronavirus
within
famili
coronavirida
divid
four
antigen
group
contain
total
serotyp
two
infecti
agent
man
singular
structur
method
replic
distinguish
virus
viru
particl
nm
diamet
contain
larg
singlestrand
rna
posit
polar
nuclear
protein
coil
intern
form
nucleocapsid
core
surround
lipid
bilay
insert
three
distinct
glycoprotein
radiat
surfac
receptor
bind
glycoprotein
initi
cell
fusion
induc
neutrahz
antibodi
product
glycoprotein
combin
neuraminidas
hemagglutin
activ
glycoprotein
bind
intern
nucleocapsid
effect
viru
bud
coronavirus
cultiv
organ
cultur
human
embryon
trachea
less
success
tissu
cultur
human
cell
serotyp
distinguish
neutral
test
commonli
immunofluoresc
elisa
test
epidemiolog
coronaviru
infect
usual
occur
winter
earli
spring
month
epidem
everi
year
two
serotyp
caus
human
infect
tend
exclus
common
cold
due
virus
infect
spread
small
particl
aerosol
mani
infect
asymptomat
may
induc
immun
respons
clinic
infect
invari
induc
detect
antibodi
howev
antibodi
titer
may
sustain
reinfect
serotyp
occur
within
month
isaac
et
al
almost
adult
detect
antibodi
serotyp
pathogenesi
clinic
diseas
featur
similar
describ
rhinovirus
howev
incub
period
usual
longer
day
ill
persist
day
patient
exhibit
mild
fever
throat
infect
cough
less
frequent
complic
infect
unusu
isol
case
pneumonia
record
virus
caus
exacerb
asthma
chronic
bronchiti
pathogenesi
infect
littl
understood
evid
suggest
slow
progress
destruct
ciliat
epithelium
diagnosi
treatment
diagnosi
coronaviru
infect
difficult
unsatisfactori
organ
cultur
sensit
viru
isol
rare
avail
tissu
cultur
system
rel
insensit
direct
demonstr
viru
cell
respiratori
secret
immunofluoresc
elisa
use
laboratori
diagnos
made
retrospect
demonstr
signific
rise
antibodi
follow
infect
schiebl
kapikian
rhinoviru
infect
treatment
symptomat
antivir
drug
develop
vaccin
avail
coronaviru
infect
experiment
ainterferon
shown
amelior
symptom
reduc
viru
replic
common
cold
character
afebril
ill
local
nasal
epithelium
present
nasal
obstruct
discharg
sneez
cough
caus
rhinovirus
coronavirus
remaind
caus
number
virus
includ
echovirus
coxsacki
b
virus
respiratori
syncyti
viru
influenza
c
parainfluenza
virus
tabl
infect
rel
mild
larg
number
agent
involv
exact
laboratori
diagnosi
seldom
undertaken
except
research
purpos
specif
treatment
virolog
serotyp
human
adenovirus
six
subgenera
genu
mastadenoviru
famili
adenovirida
eight
serotyp
three
subgenera
caus
respiratori
infect
man
tabl
viru
particl
contain
singlestrand
dna
surround
least
polypeptid
outer
capsid
made
capsomer
arrang
isocosahedr
triangl
vortic
give
particl
diamet
nm
capsomer
hexon
six
neighbor
compos
singl
protein
common
epitop
serotyp
remain
capsomer
penton
five
neighbor
compos
base
fiberlik
project
radiat
outward
serotyp
specif
human
adenovirus
replic
sequenti
human
cell
viru
particl
attach
cell
receptor
via
penton
fiber
cell
receptor
hexon
follow
entri
cellular
dna
protein
synthesi
inhibit
replic
take
place
cell
nucleu
newlyform
penton
toxic
cell
viru
releas
cell
death
divis
human
adenovirus
six
subgenera
base
sequenc
homolog
dna
genom
dna
fragment
analysi
follow
restrict
enzym
treatment
oncogen
newborn
hamster
molecular
mass
intern
protein
length
fiber
precent
g
c
viral
dna
divis
serotyp
base
neutral
test
show
crossreact
classif
import
sinc
consist
associ
virus
variou
human
infect
wadel
epidemiolog
adenovirus
caus
sporad
epidem
infect
five
per
cent
acut
respiratori
infect
ten
per
cent
febril
infect
children
togeth
infect
adult
caus
virus
pneumonia
children
due
adenoviru
infect
transmiss
respiratori
droplet
whilst
children
fecalor
transmiss
import
fecal
excret
continu
week
month
acut
infect
age
year
children
antibodi
serotyp
antibodi
serotyp
less
common
total
result
reflect
import
virus
human
infect
pathogenesi
adenovirus
spread
droplet
infect
imping
epitheli
cell
pharynx
lower
respiratori
tract
enter
kill
cell
combin
inhibit
cellular
metabol
viru
replic
toxic
effect
penton
result
extens
desquam
affect
area
caus
sore
throat
necrot
bronchiti
bronchiol
interstiti
pneumonia
lymphoid
cell
infect
caus
hypertrophi
affect
cell
harbor
latent
viru
month
year
throughout
life
although
excis
tonsil
adenoid
contain
latent
viru
evid
exacerb
except
possibl
pertussi
syndrom
clinic
diseas
adenovirus
caus
acut
respiratori
diseas
ard
seen
children
age
five
year
less
brandt
et
al
predominantli
due
serotyp
subgenera
b
frequenc
infect
children
mean
adult
infect
unusu
spread
droplet
infect
incub
period
day
symptom
begin
pharyng
cough
nasal
congest
coryza
whilst
fever
exud
tonsil
malais
headach
myalgia
often
seen
infect
tend
progress
day
period
resolv
day
infect
may
extend
caus
laryngotracheobronch
bronchiti
pneumonia
last
particularli
import
young
children
caus
death
sporad
infect
children
adult
also
caus
adenoviru
type
subgenera
c
present
laryngotracheobronch
pneumonia
commonli
seen
show
radiolog
evid
pneumonia
conjunct
infect
known
pharyngoconjunctiv
fever
occasion
seen
epidem
among
children
famili
respiratori
tract
complic
particularli
sever
immunocompromis
patient
probabl
due
overcrowd
fatigu
adenoviru
type
caus
epidem
ard
militari
recruit
recruit
becom
infect
requir
hospit
lower
respiratori
tract
infect
pneumonia
death
record
adenovirus
frequendi
isol
patient
whoop
cough
syndrom
conjunct
bordetella
pertussi
usual
report
adenoviru
type
howev
littl
evid
adenovirus
produc
syndrom
alon
presenc
adenoviru
may
due
reactiv
tonsillar
tissu
bordetella
pertussi
complic
infect
process
diagnosi
adenovirus
present
throat
swab
throat
nasal
wash
fece
infect
person
viru
growth
best
tissu
cultur
human
embryon
kidney
hela
kb
cell
avail
altern
growth
recogn
characterist
cytopath
effect
howev
may
take
day
week
develop
viru
demonstr
earli
infect
cell
immunofluoresc
specif
antibodi
isol
identifi
adenovirus
antisera
common
epitop
hexon
use
complement
fixat
immunofluoresc
elisa
test
specif
serotyp
identifi
neutral
test
effect
antivir
agent
treatment
adenoviru
infect
treatment
limit
relief
symptom
addit
adenoviru
vaccin
howev
problem
ard
militari
recruit
import
vaccin
develop
live
adenoviru
type
main
virus
respons
ard
given
oral
coat
enter
prepar
establish
intestin
infect
induc
immun
reaction
bypass
respiratori
tract
caus
symptom
tarafuji
etal
virolog
epsteinbarr
viru
eb
v
member
famili
herpetovirida
member
subfamili
gammaherpesvirina
caus
infect
human
viru
distinguish
herpetovirida
replic
establish
latent
infect
plymphocyt
potenti
promot
tumorgen
cell
viru
rel
larg
nm
diamet
particl
compos
sequenti
linear
doublestrand
dna
intern
core
protein
capsid
capsomer
arrang
icosahedr
form
protein
tegument
trilaminar
envelop
deriv
cellular
membran
insert
spike
sever
virusspecif
glycoprotein
infect
primarili
epitheli
cell
oropharynx
via
complement
receptor
viru
infect
cell
spread
plymphocyt
cell
undergo
lytic
infect
major
support
latent
infect
lead
cell
prolifer
mechan
latenc
fulli
understood
believ
due
absenc
lowlevel
host
cell
transcript
factor
essenti
viru
replic
result
persist
lifelong
plymphocyt
infect
epidemiolog
serolog
studi
develop
countri
indic
eb
v
infect
common
adult
infect
develop
countri
infect
occur
earlier
common
infect
subject
remain
viru
excretor
month
year
probabl
life
continu
viru
product
variabl
number
plymphocyt
oral
caviti
infect
accompani
intens
immun
respons
balanc
viru
product
immun
statu
determin
extent
viru
secret
one
time
immun
respons
suffici
resolv
ill
infect
lymphocyt
appear
resist
cytotox
cell
downregul
hla
antigen
express
immort
plymphocyt
polyclon
lead
cell
prolifer
exagger
immunosuppress
patient
hiv
malaria
infect
person
turn
lead
chromosom
transloc
cmyc
oncogen
come
adjac
strong
promot
outcom
malign
cell
transform
give
rise
burkitt
lymphoma
lenair
bornkamm
pathogenesi
infect
saliva
previous
infect
subject
sinc
viru
product
low
transmiss
requir
close
contact
peak
infect
seen
age
year
correspond
age
earli
adolesc
intimaci
exact
site
infect
remain
unknown
waldey
ring
rich
lymphocyt
epitheli
cell
salivari
gland
suggest
variou
author
virusinfect
dissemin
throughout
bodi
via
blood
stream
antigenposit
cell
detect
organ
tissu
infect
accompani
intens
immun
reaction
viru
prolifer
p
cell
includ
virusspecif
antibodi
heterophil
antibodi
autoantibodi
rheumatoid
factor
robinson
steven
inde
clinic
diseas
due
natur
intens
immun
respons
chang
pattern
immun
state
regul
viru
secret
infect
patient
other
clinic
featur
follow
contact
infect
saliva
incub
period
day
follow
short
prodrom
ill
headach
malais
fatigu
definit
symptom
glandular
fever
occur
patient
complain
sore
throat
hyperemia
hyperplasia
lymphoid
tissu
exhibit
exud
pharynx
fever
last
day
cervic
gener
lymphadenopathi
fever
malais
persist
week
month
secondari
infect
common
blood
dyscrasia
occur
splenic
enlarg
common
rare
lead
ruptur
mild
hepatomegali
seen
patient
associ
transient
jaundic
mild
rubilliform
skin
rash
occur
howev
ampicillin
caus
maculopapular
rash
use
patient
sore
throat
oral
caviti
obstruct
due
massiv
enlarg
tonsil
adenoid
epiglotti
may
requir
emerg
treatment
fatal
record
usual
associ
immunocompromis
patient
diagnosi
symptom
glandular
fever
usual
alert
physician
confirm
suspicion
number
laboratori
test
viru
difficult
cultiv
vitro
growth
seen
lymphocyt
cell
support
viru
replic
howev
viru
protein
dna
demonstr
infect
cell
western
blotdng
dna
hybridizafion
test
respect
serolog
test
includ
demonstr
serum
igm
antibodi
viru
capsid
protein
use
elisa
test
detecuon
heterophil
antibodi
respons
use
paul
bunnel
test
atyp
monocyt
form
peripher
blood
leucocyt
treatment
control
interferon
acyclovir
shown
diminish
viru
secret
treatment
relaps
occur
treatment
stop
importantli
neither
treatment
significantli
amelior
symptom
therefor
recommend
absenc
specif
therapi
treatment
support
sore
throat
treat
analges
suggest
corticosteroid
limit
durat
ill
possibl
effect
immun
respons
import
ebv
initi
burkitt
lymphoma
african
children
incid
focus
attent
develop
ebv
vaccin
vaccin
undergo
clinic
trial
present
time
although
febril
sore
throat
caus
adenoviru
ebv
infect
larg
number
virus
produc
clinic
symptom
includ
influenza
b
c
numer
serotyp
coxsacki
echovirus
parainfluenza
virus
collect
latter
virus
respons
half
febril
sore
throat
occur
collect
virus
respons
febril
sore
throat
caus
infecti
agent
virolog
influenza
virus
virus
genu
orthomyxoviru
famili
orthomyxovirida
affect
man
bird
hors
pig
speci
virus
approxim
spheric
diamet
nm
viru
particl
consist
singlestrand
rna
neg
polar
segment
eight
fragment
vari
size
rna
close
associ
nuclear
protein
np
polymeras
enzym
complex
form
helic
structur
np
take
one
three
antigen
form
allow
influenza
virus
classifi
type
b
c
surround
nuclear
protein
matrix
membran
protein
turn
surround
lipid
bilay
insert
bilay
radiat
surfac
two
viru
glycoprotein
numer
glycoprotein
hemagglutinin
ha
receptor
bind
compon
classif
influenza
type
subtyp
base
princip
differ
antigen
form
ha
hi
molecul
second
glycoprotein
neuraminidas
na
import
cell
infect
facilit
releas
newli
form
viru
surfac
infect
cell
na
antigen
variabl
n
variat
use
subtyp
classif
virus
influenza
virus
grow
human
monkey
cell
amniot
allanto
caviti
embryon
hen
egg
absorb
viru
uncoat
viru
rna
togeth
polymeras
enzym
complex
pass
cell
nucleu
replic
depend
cell
rna
synthesi
produc
viru
compon
pass
cell
membran
assembl
bud
cell
surfac
complet
cycl
take
hour
epidemiolog
influenza
hold
uniqu
posit
among
virus
caus
respiratori
tract
infect
sinc
commonli
dramat
caus
local
outbreak
widespread
epidem
occur
part
world
countri
year
epidem
occur
suddenli
without
warn
number
peopl
infect
rang
hundr
hundr
thousand
although
shortliv
epidem
infect
popul
clinic
diseas
occur
infect
subject
death
due
direcdi
indirectli
influenza
number
per
million
person
per
year
develop
countri
import
infect
caus
morbid
mortal
reflect
enorm
scientif
effort
made
understand
viru
natur
diseas
devis
method
control
influenza
viru
isol
crossreferenc
patient
time
place
sever
pattern
seen
firstli
pandem
widespread
epidem
caus
influenza
virus
influenza
b
virus
associ
selflimit
epidem
occur
famili
small
commun
influenza
c
viru
associ
sporad
infect
mainli
among
young
children
influenza
exhibit
greatest
antigen
divers
influenza
b
exhibit
variat
influenza
c
rel
stabl
secondli
record
pattern
influenza
epidem
past
centuri
exhibit
two
phenomena
everi
year
sinc
record
began
influenza
viru
undergon
major
antigen
chang
ha
molecul
term
antigen
shift
emerg
new
subtyp
result
pandem
seen
year
hi
caus
epidem
follow
next
new
subtyp
emerg
subtyp
distinct
immun
one
provid
protect
infect
other
origin
new
subtyp
simpl
mutat
previous
exist
strain
sinc
mani
genet
chang
occur
intermediari
strain
found
two
theori
origin
new
subtyp
advanc
firstli
two
influenza
virus
one
human
origin
probabl
avian
origin
infect
cell
due
segment
natur
viru
genom
reassort
viru
easili
produc
combin
properti
infect
man
ha
glycoprotein
nonhuman
strain
new
subtyp
caus
pandem
infect
popul
previou
immun
altern
theori
variou
subtyp
circul
sequenti
period
year
sinc
two
occas
antibodi
new
serotyp
detect
sera
elderli
peopl
year
prior
emerg
new
subtyp
caus
pandem
infect
virus
surviv
time
unknown
time
antigen
shift
epidem
occur
year
strain
caus
exhibit
antigen
drift
strain
belong
subtyp
crossreact
complet
infect
one
strain
induc
solid
immun
later
emerg
strain
sequenti
accumul
mutat
aris
natur
select
antigen
pressur
immun
partiallyimmun
popul
addit
antigen
drift
shift
virus
isol
differ
place
time
even
virus
differ
individu
epidem
exhibit
antigen
differ
known
interand
intraepidem
variat
underlin
difficulti
match
vaccin
viru
epidem
strain
contribut
disappoint
low
level
immun
induc
inactiv
influenza
vaccin
degre
crossprotect
directli
relat
degre
crossreact
viru
ha
shown
tabl
influenza
b
virus
exhibit
antigen
drift
antigen
shift
pathogenesi
pathogenesi
influenza
agre
among
research
mani
featur
understood
virolog
investig
indic
infect
viru
inhal
droplet
epitheli
cell
upper
lower
respiratori
airway
histolog
studi
nasal
exud
tracheal
biopsi
indic
major
site
infect
ciliat
columnar
epitheli
cell
becom
progress
round
swollen
exhibit
vacuol
loss
ciliat
progress
usual
begin
tracheal
bronchial
epithelium
ascend
result
widespread
destruct
ciliat
epithelium
basement
membran
affect
lesion
becom
increasingli
permeabl
polymorphonuclear
infiltr
edema
gener
symptom
uncompl
influenza
virem
spread
suspect
howev
conclus
evid
viremia
occur
contrast
viru
infect
associ
ecg
eeg
chang
unconfirm
observ
viru
antigen
brain
heart
tissu
publish
infect
associ
viral
enceph
particularli
among
children
find
suggest
dissemin
either
viru
viru
product
respiratori
tract
viru
known
grow
leucocyt
releas
pyrogen
cytokin
offer
explan
system
symptom
clinic
diseas
symptom
influenza
tend
constant
regardless
subtyp
strain
viru
howev
clinic
featur
influenza
young
children
may
vari
adult
croup
common
symptom
children
sore
throat
common
adult
droplet
infect
follow
incub
period
approxim
hour
onset
ill
usual
abrupt
symptom
includ
fever
headach
photophobia
shiver
dri
cough
malais
ach
muscl
dri
tick
throat
lead
voic
becom
huski
lost
eye
often
wateri
burn
pain
movement
fever
usual
continu
typic
last
day
percentag
patient
second
rise
temperatur
may
occur
usual
smaller
first
give
infect
biphas
fever
curv
cough
may
persist
sever
day
nose
block
show
purul
discharg
myalgia
sever
leg
muscl
also
may
involv
extrem
acut
ill
usual
resolv
within
day
patient
frequent
complain
feel
listless
week
depress
common
residu
complaint
infect
caus
influenza
b
resembl
close
caus
influenza
contrast
influenza
c
usual
mild
upper
respiratori
tract
infect
complic
infect
includ
tracheobronch
bronchiol
patient
exhibit
product
cough
chest
tight
crepit
commonli
heard
lung
usual
radiolog
clear
complic
conmionli
seen
patient
obstruct
bronchiti
older
peopl
death
influenza
result
patient
pneumonia
patient
influenza
viru
infect
primari
secondari
viral
pneumonia
patient
develop
persist
fever
leucocytosi
dyspnea
hypoxia
cyanosi
follow
acut
symptom
describ
sputum
specimen
show
bacteri
caus
proport
patient
die
diffus
hemorrhag
pneumonia
commonli
pneumonia
follow
influenza
due
secondari
bacteri
infect
princip
staphylococcu
aureu
also
streptococcu
pneumonia
hemophilu
influenza
bacteri
speci
complic
major
caus
death
among
elderli
peopl
underli
diseas
congest
heart
failur
chronic
bronchiti
addit
patient
diabet
renal
diseas
alcohol
pregnant
also
increas
suscept
secondari
bronchopneumonia
influenza
also
associ
myalgia
common
featur
acut
diseas
clinic
myositi
myoglobinuria
occur
symptom
develop
onset
respiratori
infect
muscl
becom
pain
tender
without
neurolog
symptom
import
complic
influenza
infect
syndrom
known
rey
syndrom
character
encephalopathi
fatti
liver
degener
chiefli
seen
age
year
among
hospit
mortal
high
associ
rey
syndrom
follow
infect
influenza
b
virus
fulli
demonstr
pathogenesi
remain
obscur
carey
et
al
research
highlight
associ
viru
infect
treatment
fever
high
concentr
aspirin
reason
aspirin
given
patient
age
group
conjectur
associ
influenza
infect
pregnanc
congenit
abnorm
justifi
current
knowledg
complic
report
ketoacidosi
diabet
patient
acut
viral
enceph
children
guillainbarr
syndrom
sudden
infant
death
syndrom
toxic
shock
syndrom
result
dual
associ
staphylococcu
aureu
influenza
infect
diagnosi
influenza
virus
recov
throat
wash
swab
inocul
tissu
cultur
kidney
tissu
rhesu
monkey
chick
varieti
speci
incub
newli
produc
viru
detect
supernat
fluid
abil
agglutin
erythrocyt
hemagglutin
adher
erythrocyt
viru
particl
assembl
cell
surfac
hemadsorpt
influenza
viru
also
cultur
amniot
caviti
embyron
egg
incub
high
titer
viru
found
amniot
fluid
detect
hemagglutin
virus
recogn
influenza
b
c
complement
fixat
test
use
extract
infect
cell
contain
high
concentr
np
antigen
typespecif
antisera
identif
influenza
isol
subtyp
strain
depend
upon
antigen
differ
ha
determin
hemagglutin
inhibit
hi
test
antisera
rais
experiment
anim
rang
viru
subtyp
strain
titer
antisera
homolog
viru
known
prior
test
pattern
hi
titer
found
unknown
influenza
viru
determin
strain
type
howev
highli
special
type
system
respons
refer
laboratori
constantli
type
new
isol
virus
worldwid
endeavor
detect
new
viru
variant
aris
proof
influenza
infect
also
obtain
demonstr
rise
specif
complement
fixat
hi
antibodi
sera
collect
earli
onset
symptom
day
later
control
treatment
constant
almost
annual
antigen
chang
seen
influenza
viru
lesser
extent
influenza
b
mean
vaccin
need
develop
new
epidem
strain
present
vaccin
produc
inocul
viru
embryon
egg
purifi
inactiv
result
viru
growth
give
whole
viru
disrupt
viru
viru
subunit
ha
na
vaccin
potter
date
live
attenu
viru
vaccin
avail
inactiv
vaccin
produc
reaction
mild
ephemer
induc
serum
antibodi
major
subject
immun
vaccine
due
sever
fatal
influenza
vaccin
offer
annual
atrisk
patient
includ
person
age
yr
age
patient
histori
chronic
chest
heart
diseas
patient
asthma
renal
dysfunct
metabol
disord
year
new
subtyp
recogn
key
personnel
industri
social
servic
offer
vaccin
present
treatment
influenza
symptomat
patient
advis
remain
bed
day
acut
symptom
subsid
symptom
headach
fever
treat
paracetamol
codein
linctu
reliev
cough
insomnia
may
treat
barbitur
promethazin
antibiot
indic
chest
complic
present
suspect
use
prophylact
antibiot
patient
chronic
chest
diseas
common
recommend
compound
amantadin
analog
rimantidin
activ
influenza
oral
dose
mg
per
day
given
peopl
contact
influenza
decreas
chanc
infect
given
patient
clinic
diseas
reduc
length
sever
diseas
dolin
et
al
virolog
parainfluenza
virus
genu
paramyxoviru
famili
paramyxovirida
distinguish
size
shape
nucleocapsid
biochem
similar
antigen
crossreact
presenc
surfac
glycoprotein
combin
hemagglutin
neuraminidas
activ
viru
particl
consist
singl
nonseg
negativestrand
rna
three
intern
protein
surround
lipid
bilay
fourth
protein
insert
hemagglutininneuraminidas
molecul
fusion
protein
radiat
surfac
virion
particl
complet
virion
diamet
nm
virus
replic
primari
human
monkey
cell
assembl
new
viru
particl
take
place
cytoplasm
releas
bud
effect
cell
lytic
cytopath
effect
occasion
syncytia
format
virus
detect
hemadsorpt
guineapig
erythrocyt
infect
cell
virion
particl
bud
cell
membran
four
serotyp
caus
respiratori
infect
man
individu
recogn
variou
test
includ
hemagglutin
inhibit
hemadsorpt
inhibit
neutral
test
epidemiolog
parainfluenza
virus
type
major
caus
tracheobronch
croup
young
children
type
frequent
associ
pneumonia
type
caus
mild
upper
respiratori
tract
infect
infect
droplet
requir
small
dose
viru
viru
infect
person
shed
day
case
continu
week
infect
type
worldwid
peak
number
occur
winter
month
epidem
frequent
record
reinfect
common
chapman
et
al
antibodi
one
virus
age
year
age
year
pathogenesi
mild
infect
mostli
nose
throat
minim
involv
lower
respiratori
tract
extens
infect
type
involv
larynx
trachea
bronchi
pneumonia
occur
patient
type
infect
caus
higher
incid
bronchiol
pneumonia
viru
replic
lytic
effect
epitheli
cell
whilst
trachea
bronchi
infect
caus
excess
mucu
product
lead
atelectasi
pneumonia
infect
induc
ige
antibodi
respons
seriou
case
turn
initi
histamin
releas
thought
respons
import
pathogenesi
infect
clinic
featur
follow
incub
period
day
primari
infect
children
seen
rhiniti
pharyng
erythema
evid
bronchiti
commonli
seen
hoars
cough
croup
bronchiti
rhonchi
fever
record
last
day
sever
case
infect
extend
produc
heighten
fever
laryngotracheobronch
bark
cough
croup
last
hour
symptom
may
worsen
caus
air
hunger
cyanosi
sternal
intercost
retract
airway
obstruct
glottic
subglott
narrow
parrott
et
al
pneumonia
develop
cough
product
radiolog
examin
may
show
interstiti
perihylar
infiltr
diagnosi
virus
present
throat
wash
cultiv
monkey
kidney
cell
replic
viru
particl
demonstr
surfac
infect
cell
hemadsorpt
altern
viru
detect
directli
immunofluoresc
test
respiratori
secret
ray
minnich
diagnosi
base
serolog
test
less
satisfactori
primari
infect
induc
typespecif
antibodi
respons
detect
hemagglutin
inhibit
complement
fixat
neutral
test
subsequ
infect
induc
heterotyp
respons
control
treatment
much
research
carri
develop
parainfluenza
viru
vaccin
none
avail
present
time
inactiv
vaccin
induc
serum
antibodi
partial
immun
treatment
symptomat
children
may
nurs
plastic
tent
suppli
cool
moisten
oxygen
day
reliev
respiratori
symptom
sever
obstruct
may
requir
endotrach
intub
tracheostomi
accumul
excess
tracheobronchi
secret
may
requir
bronchoscopi
aspir
antibiot
use
investig
indic
secondari
bacteri
infect
use
corticosteroid
contenti
aerosol
prepar
antivir
compound
ribavirin
may
valuabl
case
laryngotrach
croup
children
age
three
year
due
parainfluenza
viru
infect
remain
case
due
influenza
b
respiratori
syncyti
viru
rsv
variou
serotyp
coxsacki
echovirus
sever
infect
indic
laboratori
investig
thu
contribut
latter
agent
syndrom
welldocu
acut
bronchiti
commonli
tracheobronch
sinc
contigu
respiratori
compart
usual
involv
associ
adenoviru
type
infect
children
adult
serotyp
identifi
among
infect
caus
bronchiti
rhinovirus
rsv
viru
children
measl
influenza
viru
infect
children
adult
infect
may
preced
secondari
bacteri
infect
exacerb
chronic
bronchiti
frequent
associ
viru
infect
includ
wide
rang
virus
commonli
caus
rsv
rhinovirus
parainfluenza
virus
virolog
respiratori
syncyti
viru
rsv
belong
genu
pneumoviru
within
famili
paramyxovirida
distinguish
form
nucleocapsid
replic
entir
cell
cytoplasm
absenc
hemagglutinin
neuraminidas
glycoprotein
viru
particl
structur
similar
member
famili
consist
singl
nonseg
neg
strand
rna
three
intern
protein
surround
lipid
bilay
two
associ
protein
insert
outer
aspect
lipid
bilay
spike
attach
protein
fusion
protein
diamet
virion
nm
rsv
replic
cytoplasm
rang
human
anim
cell
cell
death
princip
result
cell
fusion
format
multinucl
syncytia
indic
presenc
viru
give
viru
name
antigen
variant
known
result
recognit
two
subgroup
epidemiolog
rsv
caus
annual
epidem
winter
month
countri
indic
abrupt
rise
number
pediatr
admiss
hospit
glezen
denni
infect
spread
larg
droplet
therefor
requir
close
contact
hand
nasal
conjunctiv
secret
via
inanim
object
selfinocul
viru
highli
infecti
children
infect
year
life
children
age
year
recurr
infect
common
viru
caus
bronchiol
pneumonia
case
seen
children
year
age
mortal
rate
children
underli
heart
respiratori
diseas
infect
essenti
upper
respiratori
tract
infect
children
age
less
week
month
howev
age
limit
infect
involv
lower
respiratori
tract
recoveri
accompani
serum
antibodi
cellmedi
immun
respons
protect
subsequ
lower
respiratori
tract
infect
local
iga
antibodi
respons
ephemer
allow
upper
respiratori
tract
infect
later
life
pathogenesi
incub
period
day
infect
begin
nasopharynx
viru
titer
reach
maximum
day
declin
day
detect
patient
week
spread
lower
respiratori
tract
celltocel
interact
respiratori
epithelium
via
aspir
cell
infect
cytopath
follow
cell
fusion
caus
inflamm
necrosi
associ
plug
airway
factor
involv
diseas
fulli
defin
includ
immunopatholog
due
antibodi
product
format
antigenantibodi
complex
delay
hypersensit
reaction
exagger
cytotox
tcell
respons
ige
respons
describ
parainfluenza
viru
infect
welliv
et
al
clinic
diseas
children
age
less
week
greater
month
infect
usual
seen
upper
respiratori
tract
urt
infect
rhiniti
mild
fever
sneez
wheez
children
exhibit
lower
respiratori
tract
involv
tachypnea
rale
rhonchi
sever
lower
respiratori
tract
lrt
infect
may
occur
common
age
week
follow
mainli
urt
infect
patient
develop
bronchiol
dyspnea
sever
tachypnea
intercost
substern
retract
sever
case
ad
pneumonia
occur
hypoxia
cyanosi
radiolog
appear
vari
normal
bacteri
pneumonia
clinic
sever
mirror
radiolog
chang
infect
last
day
patient
show
improv
day
sever
case
symptom
may
persist
sever
week
diagnosi
aspir
nasal
secret
contain
viru
detect
inocul
tissu
cultur
show
syncytia
format
follow
viru
replic
direct
test
viru
antigen
use
immunofluoresc
test
infect
induc
rise
serum
antibodi
detect
complement
fixat
neutral
test
treatment
patient
lrt
infect
commonli
requir
hospit
support
therapi
reduct
fever
hydrat
commonli
adequ
sever
case
oxygen
may
requir
assist
breath
mechan
remov
respiratori
secret
may
necessari
blood
gase
monitor
infect
respond
treatment
antivir
compound
ribovirin
administr
compound
small
particl
aerosol
proven
effect
hall
et
al
effect
vaccin
develop
despit
year
dedic
research
studi
shown
bronchiol
case
caus
rsv
character
necrosi
slough
bronchiolar
epitheli
lead
plug
small
airway
obstruct
atelectasi
hall
et
al
howev
virus
appropri
associ
compart
respiratori
tract
produc
patholog
chang
clinic
symptom
thu
bronchiol
associ
infect
influenza
virus
b
adenovirus
young
children
parainfluenza
viru
infect
viru
infect
describ
separ
head
pneumonia
character
radiolog
chang
physic
sign
patholog
uncommonli
relat
infect
viru
howev
three
reserv
admit
firstli
case
acut
pneumonia
due
adenoviru
influenza
virus
although
unusu
welldocu
fatal
record
follow
infect
secondli
sever
infect
virus
higher
compart
respiratori
tract
extend
caus
pneumonia
includ
adenoviru
influenza
virus
rsv
parainfluenza
virus
young
children
thirdli
primari
pneumonia
rare
present
measl
chicken
pox
varicellazost
cytomegaloviru
cmv
infect
although
unusu
normal
subject
commonli
seen
immunocompromis
person
infect
devast
pneumonia
immunocompromis
measl
chicken
pox
cmv
usual
extens
typic
infect
involv
lung
present
without
rash
atyp
rash
patient
histori
infect
patient
develop
cough
chest
pain
serious
dyspnea
cyanosi
xray
may
show
evid
viral
pneumonia
atyp
patchi
consolid
death
record
immunocompromis
patient
patholog
alveoli
contain
edema
fluid
macrophag
polymorphonuclear
cell
typic
diagnost
giant
multinuclear
cell
virus
grown
bronchial
secret
howev
sinc
rapidli
progress
infect
suggest
treatment
avail
two
virus
quicker
method
direct
demonstr
viru
immunofluoresc
eli
test
cell
secret
need
treatment
measl
viru
pneumonia
acyclovir
ganciclovir
report
valu
treatment
cmv
acyclovir
prevent
pneumonia
chicken
pox
patient
proven
valu
treat
establish
pneumonia
respiratori
tract
infect
among
commonest
ill
individu
experi
two
five
infect
year
live
ill
vari
rel
mild
common
cold
caus
rhinovirus
coronavirus
sever
bronchiol
pneumonia
caus
adenovirus
influenza
virus
respiratori
syncyti
viru
rsv
infant
former
associ
littl
morbid
mortal
influenza
respons
annual
thousand
death
per
million
popul
virus
caus
respiratori
tract
infect
ad
complic
influenza
virus
new
antigen
variant
recogn
almost
annual
immun
infect
one
viru
strain
offer
littl
protect
infect
other
knowledg
mechan
spread
respiratori
virus
larg
understood
help
infect
control
howev
clinic
sign
symptom
infect
tend
diagnost
caus
agent
although
vaccin
develop
seriou
infect
influenza
adenoviru
infect
none
avail
import
infect
treatment
larg
symptomat
compound
ribovirin
rsv
infect
amantadin
influenza
viru
infect
shown
effect
much
remain
discov
effect
measur
implement
limit
enorm
cost
incur
infect
number
virus
involv
larg
spectrum
ill
complex
present
chapter
virus
describ
togeth
featur
epidemiolog
pathogenesi
clinic
diseas
treatment
